Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation

Area of Science:

• Nanomedicine
• Toxicology
• Oncology

Background:

• The rapid advancement of nanomedicine necessitates robust safety research to support clinical translation.
• Existing safety data from liposomal formulations in oncology provides a foundation but is insufficient for emerging platforms.

Purpose of the Study:

• To discuss experiences from liposomal nanomedicine safety data in oncology.
• To identify new challenges in nanomedicine safety research beyond liposomes.
• To propose a framework for generating regulatory-ready safety data for nanomedicines.

Main Methods:

• Review of safety data from established liposomal nanomedicines.
• Identification of emerging challenges in nanomedicine development.
• Emphasis on integrating predictive toxicology, ADME/toxicokinetics, manufacturing risks, material properties, and novel safety endpoints.

Main Results:

• Lessons learned from liposomal oncology formulations highlight the need for comprehensive safety assessments.
• The expansion of nanomedicine platforms presents unique safety challenges requiring new investigation strategies.
• A combined approach using predictive toxicology and detailed characterization is essential.

Conclusions:

• Strategic planning of nanosafety research is vital for enabling clinical trials and patient safety.
• A rational infrastructure for regulatory decision-making requires robust investigational new drug-enabling safety data.
• Thorough evaluation of physicochemical properties is critical for assessing nanomedicine hazards.